Back to Search
Start Over
Cisplatin and etoposide: an effective treatment for refractory breast carcinoma
- Source :
- American journal of clinical oncology. 12(1)
- Publication Year :
- 1989
-
Abstract
- Thirty-one patients with metastatic breast carcinoma refractory to standard hormonal and chemotherapy were treated with cisplatin 100 mg/m2 per course and etoposide 300 mg/m2 per course divided over 5 days. Courses were repeated at 3-6-week intervals, depending on the speed of recovery from myelosuppression. Of 29 evaluable patients, three had complete responses, eight had partial responses, eight had stable disease, and 10 had progressive disease. Nausea, emesis, anorexia, weakness, and easy fatigability were common but tolerable side effects. Myelosuppression was frequent and occasionally profound but there were no deaths from hemorrhage or infection. No significant renal toxicity was encountered. The combination of cisplatin and etoposide has sufficient antitumor activity with acceptable toxicity in heavily pretreated patients to justify its further study in breast cancer.
- Subjects :
- Oncology
Adult
Cancer Research
medicine.medical_specialty
Nausea
medicine.medical_treatment
Breast Neoplasms
Adenocarcinoma
Drug Administration Schedule
Breast cancer
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Neoplasm Metastasis
Etoposide
Aged
Cisplatin
Chemotherapy
Clinical Trials as Topic
business.industry
Middle Aged
medicine.disease
Toxicity
Female
medicine.symptom
business
Breast carcinoma
Progressive disease
medicine.drug
Subjects
Details
- ISSN :
- 02773732
- Volume :
- 12
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- American journal of clinical oncology
- Accession number :
- edsair.doi.dedup.....6f367efd1e4170d2c03adb596e5666da